Talphera (NASDAQ:TLPH) Upgraded to Strong-Buy at RODMAN&RENSHAW

Talphera (NASDAQ:TLPH) was upgraded by stock analysts at RODMAN&RENSHAW to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

A number of other brokerages also recently issued reports on TLPH. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Talphera in a report on Tuesday, January 21st. Rodman & Renshaw started coverage on shares of Talphera in a report on Tuesday. They issued a “buy” rating and a $4.00 target price for the company. Finally, Maxim Group raised Talphera to a “strong-buy” rating in a research note on Friday, November 8th.

Talphera Stock Performance

NASDAQ:TLPH opened at $0.73 on Tuesday. Talphera has a 1 year low of $0.50 and a 1 year high of $1.61. The stock has a fifty day moving average price of $0.65 and a two-hundred day moving average price of $0.81. The stock has a market capitalization of $12.40 million, a price-to-earnings ratio of -1.06 and a beta of 0.28.

Institutional Investors Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Rosalind Advisors Inc. bought a new position in shares of Talphera, Inc. (NASDAQ:TLPH) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera comprises 0.4% of Rosalind Advisors Inc.’s portfolio, making the stock its 25th largest holding. Rosalind Advisors Inc. owned about 4.47% of Talphera at the end of the most recent reporting period. Hedge funds and other institutional investors own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.